Toxicology Letters, 68 (1993) 333–334
Elsevier Science Publishers B.V.

AUTHOR INDEX VOL. 68 (1993)

Ali, B., see Siddiqui, A., 301
Andersen, M.E., see Mills, J.J., 177
Arias, R.N. and de Peretti, A.F., Effects of 2,4-dichlorophenoxyacetic acid on *Rhizobium* sp. growth and characterization of its transport, 267

Brashear, W.T., see Dodd, D.E., 37
Bull, R.J., Templin, M., Larson, J.L. and Stevens, D.K., The role of dichloroacetate in the hepatocarcinogenicity of trichloroethylene, 203

Caldwell, D.J., Use of alternative endpoints with the UPitt II method for assessing the toxicity of smoke, 241
Clewell III, H.J., see Gearhart, J.M., 131
Clewell III, H.J., Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing, 101
Channel, S.R. and Hancock, B.L., Application of kinetic models to estimate transit time through cell cycle compartments, 213

DelRaso, N.J., In vitro methodologies for enhanced toxicity testing, 91
Dodd, D.E., Brashear, W.T. and Vinegar, A., Metabolism and pharmacokinetics of selected Halon replacement candidates, 37
Dodd, D.E., see McDougal, J.N., 31

Fisher, J.W., Estimating the risks of liver and lung cancer in humans exposed to trichloroethylene using a physiological model, 127
Fisher, J.W., see Gearhart, J.M., 131
Flemming, C.D., see Gearhart, J.M., 131
Frazier, J.M., In vitro models for toxicological research and testing, 73
Frederick, C.B., Limiting the uncertainty in risk assessment by the development of physiologically based pharmacokinetic and pharmacodynamic models, 159

Gearhart, J.M., Mahle, D.A., Greene, R.J., Seckel, C.S., Flemming, C.D., Fisher, J.W. and Clewell III, H.J., Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE), 131
Gibson, G.G., Peroxisome proliferators: Paradigms and prospects, 193
Grabau, J.H., Animal issues and society, 51
Green, S., Regulatory agency considerations and requirements for validation of toxicity test alternatives, 119
Greene, R.J., see Gearhart, J.M., 131

Hancock, B.L., see Channel, S.R., 213
Hansen, L.G., see Ness, D.K., 311
Harkema, J.R. and Hotchkiss, J.A., Ozone- and endotoxin-induced mucous cell metaplasias in rat airway epithelium: Novel animal models to study toxicant-induced epithelial transformation in airways, 251
Hiller, R.G., see Wilkinson, J.M., 285
Hotchkiss, J.A., see Harkema, J.R., 251
Huang, Y.-S. and Sultatos, L.G., Glutathione-dependent biotransformation of methyl parathion by mouse liver in vitro, 275

Kienholz, E., see Siblerud, R.L., 307
Kolmer, J.W., Current DoD policy on use of animals in research, 59
Komulainen, H., see Risto, L., 325
Kucharz, E.J. and Olczyk, K., Influence of chronic intoxication with selenium on collagen and elastin content in tissues of rat, 295

Larson, J.L., see Bull, R.J., 203
Li, K., see Wilkinson, J.M., 285

Mahle, D.A., see Gearhart, J.M., 131
McDougal, J.N. and Dodd, D.E., Air Force approach to risk assessment for Halon replacements, 31
McMaster, S.B., Developmental toxicity, reproductive toxicity, and neurotoxicity as regulatory endpoints, 225
Mills, J.J. and Andersen, M.E., Dioxin hepatic

carcinogenesis: Biologically motivated modeling and risk assessment, 177
Morehouse, E.T., Overview – Air Force policy on halons, 11
Moshtaghian, J., see Ness, D.K., 311
Motl, J., see Siblerud, R.L., 307

Ness, D.K., Schantz, S.L., Moshtaghian, J. and Hansen, L.G., Effects of perinatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat, 311

O'Flaherty, E.J., A pharmacokinetic model for chromium, 145
Olczyk, K., see Kucharz, E.J., 295

de Peretti, A.F., see Arias, R.N., 267
Pollard, I., see Wilkinson, J.M., 285

Risto, L., Vartiainen, T. and Komulainen, H., Formation of methemoglobin by 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone, MX, in rat erythrocytes in vitro, 325
Rowan, A.N., Formulation of ethical standards for use of animals in medical research, 63
Rubenstein, R., Human health and environmental toxicity issues for evaluation of halon replacements, 21

Schantz, S.L., see Ness, D.K., 311
Seckel, C.S., see Gearhart, J.M., 131
Siblerud, R.L., Kienholz, E. and Motl, J., Evidence that mercury from silver dental fillings may be an etiological factor in smoking, 307
Siddiqui, A., Ali, B. and Srivastava, S.P., Effect of mancozeb on hepatic glutathione *S*-transferase in rat, 301
Srivastava, S.P., see Siddiqui, A., 301
Stevens, D.K., see Bull, R.J., 203
Sultatos, L.G., see Huang, Y.-S., 275

Templin, M., see Bull, R.J., 203
Tilson, H.A., Neurobehavioral methods used in neurotoxicological research, 231
Trochimowicz, H.J., Industrial research on alternative fluorocarbons, 25

Vartiainen, T., see Risto, L., 325
Vinegar, A., see Dodd, D.E., 37

Walsh, D.A., see Wilkinson, J.M., 285
Wilkinson, J.M., Pollard, I., Walsh, D.A., Hiller, R.G. and Li, K., Caffeine does not increase synthesis of heat shock proteins in rat embryos, 285

Toxicology Letters, 68 (1993) 335–336
Elsevier Science Publishers B.V.

SUBJECT INDEX VOL. 68 (1993)

Air Force halon uses, 11
Air Force Regulation 19-15, 11
Airway epithelium, 251
Alternative end points, 241
Alternatives, 119
Animal activists, 51
Animal issues, 51
Animal patents, 51
Animal research, 51, 63
Animal rights, 63, 51
Animal use, 51
Animal welfare, 51
Animals in research, 59
Arsenate, 267

Behavioral toxicology, 231
Biologically based risk assessment, 159

Caffeine, 285
Cancer risk assessment, 159
Carcinogenesis, 213
Cardiotoxicity, 21
Cell cycle, 213
Chemical risk assessment, 101
Chloramphenicol, 267
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone, 325
Chromium, 145
Collagen, 295
Combustion toxicology, 241
Cytochrome P-450, 177
Cytochrome P4504 family, 193
2,4-D, 267

Dental amalgam, 307
Department of Defense, 59
Developmental toxicity, 225
Dichloroacetate, 203

Elastin, 295
Endotoxin, 251
Ethics, 63
Ethyl acrylate, 159

Fire extinguishing, 21
Fluorocarbon alternatives, 25

Glutathione, 275
Glutathione *S*-transferase, 301
Growth factor, 177

Halon 1211, 37
Halon replacement, 31
Halon replacements, 11
Halon substitute, 21
HCFC-123, 37, 25
HCFC-124, 37, 25
HCFC-142b, 37
Hemoglobin, 325
Hepatocarcinogenicity, 193, 203
Hepatocyte, 91
HFC-125, 25
HFC-134a, 25
hsp 25, 285
hsp 70, 285
hsp 90, 285
Hydrochlorofluorocarbon, 37
Hydrochlorofluorocarbons, 25
Hydrofluorocarbons, 25
Hydroxyproline, 295

In vitro, 91, 119, 73
In vitro methods, 101

Kinetic model, 213

Mancozeb, 301
Mercury, 307
Methemoglobin, 325
Methods, 91, 231
Methyl parathion, 275
Model, 177
Mucous cell metaplasia, 251

Neurotoxicity, 225
Neurotransmitter, 307
Nonmutagenic carcinogen, 193

Organophosphate biotransformation, 275
Oxidative damage, 325

Ozone, 251

PBPK, 177
PBPK modeling, 101
PCB, 311
Perchloroethylene, 131
Perfluorohexane, 37
Perinatal, 311
Peroxisome proliferator, 193
Pharmacokinetic models, 31
Pharmacokinetics, 101
Physiological modeling, 101
Physiologically based model, 145
Physiologically based pharmacokinetic modeling, 127
Physiologically based pharmacokinetic (PBPK) model, 131, 159

Rat, 311, 145
Rat embryo, 285
Rat liver, 301
Regulation, 59
Rhizobium, 267
Risk assessment, 127, 225, 31, 131

Screens, 91
Smoke toxicity, 241
Smoking, 307
Sodium azide, 267
Sodium selenite, 295

TCDD, 177
Test guidelines, 225
Tetrachloroethylene, 131
Thyroid, 311
Thyroxine, 311
Tier-testing, 231
Toxicity, 119
Toxicity testing, 73
Trichloroacetate, 203
Trichloroethylene, 127, 203
Trifluoroacetic acid, 37
Triiodothyronine, 311
Tumor promotion, 177

Uncertainty in cancer risk assessment, 159
UPitt II method, 241
Uptake, 267

Validation, 119, 73

Water chlorination, 325